论文部分内容阅读
目的 探讨复方软肝方治疗慢性乙肝病人肝纤维化的临床效果。方法 48例慢性乙肝肝纤维化病人分为A、B、C三组 ,分别以复方软肝方、γ 干扰素和常规疗法进行治疗 ,治疗前后用RIA法检测病人血清透明质酸酶 (HA)、层粘连蛋白 (LN)、Ⅲ型前胶原 (PCⅢ )、Ⅳ型胶原 (CⅣ )四项与肝纤维化形成相关的生化指标含量 ,并作治疗前后对比。结果 复方软肝方、γ 干扰素都具有降低慢性乙肝病人肝纤维化形成相关生化指标作用 ,两种药物在降低肝纤维化相关生化指标之间差异无显著意义 (P >0 0 5 )。结论 复方软肝方、γ 干扰素对慢性乙肝肝纤维化病人均具有治疗作用
Objective To investigate the clinical effect of compound Ruangan prescription on liver fibrosis in chronic hepatitis B patients. Methods 48 chronic hepatitis B patients with chronic hepatitis B were divided into three groups: A, B and C. The patients were treated with Compound Ruangan Decoction, Interferon Gamma Intervention and conventional therapy respectively. Serum hyaluronidase (HA) , Laminin (LN), type Ⅲ procollagen (PC Ⅲ) and type Ⅳ collagen (C Ⅳ) in liver fibrosis. The biochemical parameters were compared before and after treatment. Results Compound Ruangan Prescription and interferon-γ all had the effect of reducing the biochemical index of liver fibrosis in chronic hepatitis B patients. There was no significant difference between the two drugs in reducing the biochemical indexes of liver fibrosis (P> 0.05). Conclusions Fufang Ruangan Decoction and interferon-γ have a therapeutic effect on patients with chronic hepatitis B